(2S,3R,4S,5R)-2-[(2R,3S,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxyoxane-3,4,5-triol

Term ID

CHEBI:151424

Synonyms

beta-D-xylo-pentopyranosyl-(1->2)-[beta-D-xylo-pentopyranosyl-(1->4)]-D-gluco-hexopyranose
WURCS=2.0/2,3,2/[a2122h-1x_1-5][a212h-1b_1-5]/1-2-2/a2-b1_a4-c1
Xyl(b1-2)[Xyl(b1-4)]Glc

Definition

References

GlyGen:G47969LP
GlyTouCan:G47969LP

Ontology

ChEBI ( EBI )

Relationships

Phenotype

Phenotype resulting from (2S,3R,4S,5R)-2-[(2R,3S,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxyoxane-3,4,5-triol

Phenotype where environments contain (2S,3R,4S,5R)-2-[(2R,3S,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxyoxane-3,4,5-triol

Phenotype modified by environments containing (2S,3R,4S,5R)-2-[(2R,3S,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxyoxane-3,4,5-triol

Phenotype affecting (2S,3R,4S,5R)-2-[(2R,3S,4S,5R)-4,6-Dihydroxy-2-(hydroxymethyl)-5-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-3-yl]oxyoxane-3,4,5-triol

Human Disease Model